AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The DESTINY-Endometrial01 study, officially titled ‘An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer,’ aims to evaluate the efficacy of T-DXd combined with either rilvegostomig or pembrolizumab compared to standard chemotherapy with pembrolizumab. This study is significant as it targets a specific subset of endometrial cancer patients, potentially offering new first-line treatment options.
The interventions being tested include Trastuzumab deruxtecan (T-DXd), an experimental therapy, combined with either Rilvegostomig or Pembrolizumab, both administered via intravenous infusion. These are compared against a standard chemotherapy regimen of Carboplatin and Paclitaxel with Pembrolizumab.
The study is designed as an interventional, randomized, parallel assignment with no masking, meaning all participants and researchers know which treatment is being administered. The primary purpose is treatment, focusing on progression-free survival as the main outcome.
The study began on March 27, 2025, with the primary completion and estimated completion dates yet to be announced. The latest update was submitted on August 19, 2025, indicating the study is actively recruiting participants.
The update on this study could influence AstraZeneca’s stock performance positively, as successful results may enhance its oncology portfolio and investor confidence. Competitors in the oncology space will be closely monitoring these developments, as advancements in treatment options could shift market dynamics.
The DESTINY-Endometrial01 study is ongoing, with further details available on the ClinicalTrials portal.